Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial

Miner Shao; Jie Yao; Yunke Wang; Lufeng Zhao; Baizhou Li; Lili Li; Zuqun Wu; Zexin Chen; Junqiang Fan; Fuming Qiu

doi:10.1038/s41392-023-01355-1

Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial

Signal Transduct Target Ther. 2023 Apr 10;8(1):146. doi: 10.1038/s41392-023-01355-1.

Authors

Miner Shao^#^{1

2

3}, Jie Yao^#⁴, Yunke Wang^#^{1

2

3}, Lufeng Zhao^#⁴, Baizhou Li⁵, Lili Li^{1

2

3}, Zuqun Wu⁶, Zexin Chen⁷, Junqiang Fan⁸, Fuming Qiu^{9

10

11

12}

Affiliations

¹ Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
² Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
³ Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁴ Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁵ Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁶ Department of Respiratory Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁷ Department of Biostatistics, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
⁸ Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. zrxwk@zju.edu.cn.
⁹ Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. qiufuming@zju.edu.cn.
¹⁰ Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. qiufuming@zju.edu.cn.
¹¹ Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. qiufuming@zju.edu.cn.
¹² Cancer Center, Zhejiang University, Hangzhou, Zhejiang, China. qiufuming@zju.edu.cn.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized* / administration & dosage
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / surgery
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / surgery
Neoadjuvant Therapy* / methods
Pneumonectomy

Substances

Antibodies, Monoclonal, Humanized
sintilimab

Associated data

ClinicalTrials.gov/NCT04459611